申请人:Taisho Pharmaceuticals Co., Ltd.
公开号:US08076502B2
公开(公告)日:2011-12-13
A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration
A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I]
[wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
一种用于治疗和预防精神疾病,如精神分裂症,焦虑和相关疾病,抑郁症,躁郁症和癫痫的有效药物。该药物拮抗II类代谢型谷氨酸受体的作用,并在口服给药时显示出高活性。该药物是2-氨基-双环[3.1.0]己烷-2,6-二羧酸酯衍生物,其化学式为[I](其中R1和R2相同或不同,均表示氢原子,C1-10烷基或类似物;X表示氢原子或氟原子;Y表示-OCHR3R4或类似物(其中R3和R4相同或不同,均表示氢原子,C1-10烷基或类似物;n表示整数1或2),其药学上可接受的盐或水合物。